Читать книгу Nanobiotechnology in Diagnosis, Drug Delivery and Treatment - Группа авторов - Страница 50

The main causes of Alzheimer's disease are the accumulation of amyloid protein in the brain and the formation of extracellular amyloid plaques. Nowadays, a great deal of attention has been given on the promising use of selenium in nanoform for the treatment of Alzheimer's disease. Preliminarily, it was shown that small‐sized SeNPs (5–15 nm) deplete the formation of amyloid β by reducing the production of ROS, which may be promising in Alzheimer's disease treatment (Nazıroğlu et al. 2017).

Huo et al. (2019) used SeNPs embedded into poly‐lactide‐co‐glycolide composites for Alzheimer's disease treatment. This system was reported to reduce the load of amyloid‐β in brain samples using transgenic mice (5XFAD) and significantly reduced the memory deficit in model mice. The authors visualized specific linking of curcumin‐loaded nanospheres to amyloid plaques by fluorescence microscopy (Huo et al. 2019). Similarly, Sialic acid (SA) modified SeNPs coated with a high‐penetration peptide for the hematoencephalic barrier, i.e. the peptide‐B6 (B6‐SA‐SeNPs), showed high permeability for the hematoencephalic barrier, and can act as a new nanoplatform for Alzheimer's disease treatment. The inhibitory effect of B6‐SA‐SeNP on amyloid aggregation has been demonstrated in PC12 and bEnd3 cells (Yin et al. 2015). Further, Yang et al. (2018) demonstrated that inclusion of resveratrol antioxidant into SeNPs can be promisingly used for the management of Alzheimer's disease (Yang et al. 2018). Therefore, both using SeNPs themselves and using nanoselenium as a drug delivery system is a promising field for developing alternative approaches for Alzheimer's disease treatment.